Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral "Multi-Biologic in a Pill" for Inflammatory Bowel ...

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US ...

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
TipRanks on MSN

Celldex announces initiation of Phase 3 trial of barzolvolimab

Celldex (CLDX) announced the initiation of its global Phase 3 trial designed to establish the efficacy and safety of barzolvolimab in adult ...

Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment ...
TipRanks on MSN

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC.
Business Wire

Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that the ...
Nasdaq

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Business Wire

Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered ...